• AC Immune SA ACIU.OQ reported a quarterly adjusted loss of 16 rappen​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -5 rappen. The mean expectation of four analysts for the quarter was for a loss of 19 rappen per share. Wall Street expected results to range from -20 rappen to -17 rappen per share.

• Revenue fell 92.3% to CHF1.14 million from a year ago; analysts expected CHF742.09 thousand.

• AC Immune SA's reported EPS for the quarter was a loss of 16 rappen​.

• The company reported a quarterly loss of CHF15.8 million.

• AC Immune SA shares had fallen by 14.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for AC Immune SA is $8.50

This summary was machine generated from LSEG data March 13 at 12:06 p.m. UTC. ​All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)